Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells

Journal of Medicinal Chemistry

Volumn 55, Issue 5, 2012, Pages 2427-2436

  Wang, Si ^a   Placzek, William J ^a   Stebbins, John L ^a   Mitra, Sayantan ^a   Noberini, Roberta ^a   Koolpe, Mitchell ^a   Zhang, Ziming ^a   Dahl, Russell ^a   Pasquale, Elena B ^a   Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PACLITAXEL; RECEPTOR, EPHA2; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863291820     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201743s     Document Type: Article

References (51)

1. Gangloff, A.; Hsueh, W. A.; Kesner, A. L.; Kiesewetter, D. O.; Pio, B. S.; Pegram, M. D.; Beryt, M.; Townsend, A.; Czernin, J.; Phelps, M. E.; Silverman, D. H. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel J. Nucl. Med. 2005, 46 (11) 1866-1871
2. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 2010, 328 (5981) 1031-1035
3. Wu, A. M.; Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates Nat. Biotechnol. 2005, 23 (9) 1137-1146
4. Jaracz, S.; Chen, J.; Kuznetsova, L. V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates Bioorg. Med. Chem. 2005, 13 (17) 5043-5054
5. Langer, R. New methods of drug delivery Science 1990, 249 (4976) 1527-1533
6. Schrama, D.; Reisfeld, R. A.; Becker, J. C. Antibody targeted drugs as cancer therapeutics Nat. Rev. Drug Discovery 2006, 5 (2) 147-159
7. van Vlerken, L. E.; Amiji, M. M. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery Expert Opin. Drug Delivery 2006, 3 (2) 205-216
8. Leader, B.; Baca, Q. J.; Golan, D. E. Protein therapeutics: a summary and pharmacological classification Nat. Rev. Drug Discovery 2008, 7 (1) 21-39
9. Marx, J. L. Monoclonal antibodies in cancer Science 1982, 216 (4543) 283-285
10. Aina, O. H.; Liu, R.; Sutcliffe, J. L.; Marik, J.; Pan, C. X.; Lam, K. S. From combinatorial chemistry to cancer-targeting peptides Mol. Pharmaceutics 2007, 4 (5) 631-651
11. Koolpe, M.; Dail, M.; Pasquale, E. B. An ephrin mimetic peptide that selectively targets the EphA2 receptor J. Biol. Chem. 2002, 277 (49) 46974-46979
12. Hatakeyama, S.; Sugihara, K.; Shibata, T. K.; Nakayama, J.; Akama, T. O.; Tamura, N.; Wong, S. M.; Bobkov, A. A.; Takano, Y.; Ohyama, C.; Fukuda, M.; Fukuda, M. N. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (49) 19587-19592
13. Cutrera, J.; Dibra, D.; Xia, X.; Hasan, A.; Reed, S.; Li, S. Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy Mol. Ther. 2011, 19 (8) 1468-1477
14. Corti, A.; Curnis, F. Tumor vasculature targeting through NGR peptide-based drug delivery systems Curr. Pharm. Biotechnol. 2011, 12 (8) 1128-1134
15. Wu, H. C.; Chang, D. K. Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy J. Oncol. 2010, 2010, 723798
16. Brown, K. C. Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications Curr. Pharm. Des. 2010, 16 (9) 1040-1054
17. Newton, J. R.; Deutscher, S. L. In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents Methods Mol. Biol. 2009, 504, 275-290
18. Yang, W.; Luo, D.; Wang, S.; Wang, R.; Chen, R.; Liu, Y.; Zhu, T.; Ma, X.; Liu, R.; Xu, G.; Meng, L.; Lu, Y.; Zhou, J.; Ma, D. TMTP1, a novel tumor-homing peptide specifically targeting metastasis Clin. Cancer Res. 2008, 14 (17) 5494-5502
19. Laakkonen, P.; Porkka, K.; Hoffman, J. A.; Ruoslahti, E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels Nat. Med. 2002, 8 (7) 751-755
20. Ruoslahti, E. Targeting tumor vasculature with homing peptides from phage display Semin. Cancer Biol. 2000, 10 (6) 435-442
21. Koivunen, E.; Arap, W.; Valtanen, H.; Rainisalo, A.; Medina, O. P.; Heikkila, P.; Kantor, C.; Gahmberg, C. G.; Salo, T.; Konttinen, Y. T.; Sorsa, T.; Ruoslahti, E.; Pasqualini, R. Tumor targeting with a selective gelatinase inhibitor Nat. Biotechnol. 1999, 17 (8) 768-774
22. Gersuk, G. M.; Corey, M. J.; Corey, E.; Stray, J. E.; Kawasaki, G. H.; Vessella, R. L. High-affinity peptide ligands to prostate-specific antigen identified by polysome selection Biochem. Biophys. Res. Commun. 1997, 232 (2) 578-582
23. Pasquale, E. B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond Nat. Rev. Cancer 2010, 10 (3) 165-180
24. Noberini, R.; Lamberto, I.; Pasquale, E. B. Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin. Cell Dev. Biol. [Online early access]. DOI: 10.1016/j.semcdb.2011.10.023. Published Online: Oct 25, 2011.
25. Ireton, R. C.; Chen, J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics Curr. Cancer Drug Targets 2005, 5 (3) 149-157
26. Wykosky, J.; Debinski, W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting Mol. Cancer Res. 2008, 6 (12) 1795-1806
27. Landen, C. N.; Kinch, M. S.; Sood, A. K. EphA2 as a target for ovarian cancer therapy Expert Opin. Ther. Targets 2005, 9 (6) 1179-1187
28. Tandon, M.; Vemula, S. V.; Mittal, S. K. Emerging strategies for EphA2 receptor targeting for cancer therapeutics Expert Opin. Ther. Targets 2011, 15 (1) 31-51
29. Biao-Xue, R.; Xi-Guang, C.; Shuan-Ying, Y.; Wei, L.; Zong-Juan, M. Epha2-dependent molecular targeting therapy for malignant tumors Curr. Cancer Drug Targets 2011, 11 (9) 1082-1097
30. Wykosky, J.; Gibo, D. M.; Debinski, W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells Mol. Cancer Ther. 2007, 6 (12, Part 1) 3208-3218
31. Sun, X. L.; Xu, Z. M.; Ke, Y. Q.; Hu, C. C.; Wang, S. Y.; Ling, G. Q.; Yan, Z. J.; Liu, Y. J.; Song, Z. H.; Jiang, X. D.; Xu, R. X. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells Cancer Lett. 2011, 312 (2) 168-177
32. Jackson, D.; Gooya, J.; Mao, S.; Kinneer, K.; Xu, L.; Camara, M.; Fazenbaker, C.; Fleming, R.; Swamynathan, S.; Meyer, D.; Senter, P. D.; Gao, C.; Wu, H.; Kinch, M.; Coats, S.; Kiener, P. A.; Tice, D. A. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo Cancer Res. 2008, 68 (22) 9367-9374
33. Scarberry, K. E.; Dickerson, E. B.; McDonald, J. F.; Zhang, Z. J. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells J. Am. Chem. Soc. 2008, 130 (31) 10258-10262
34. Mitra, S.; Duggineni, S.; Koolpe, M.; Zhu, X.; Huang, Z.; Pasquale, E. B. Structure-activity relationship analysis of peptides targeting the EphA2 receptor Biochemistry 2010, 49 (31) 6687-6695
35. Macrae, M.; Neve, R. M.; Rodriguez-Viciana, P.; Haqq, C.; Yeh, J.; Chen, C.; Gray, J. W.; McCormick, F. A conditional feedback loop regulates Ras activity through EphA2 Cancer Cell 2005, 8 (2) 111-118
36. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions Angew. Chem. 2001, 40 (11) 2004-2021
37. Deshayes, S.; Maurizot, V.; Clochard, M. C.; Baudin, C.; Berthelot, T.; Esnouf, S.; Lairez, D.; Moenner, M.; Deleris, G. "Click" conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis Pharm. Res. 2011, 28 (7) 1631-1642
38. Dijkgraaf, I.; Rijnders, A. Y.; Soede, A.; Dechesne, A. C.; van Esse, G. W.; Brouwer, A. J.; Corstens, F. H.; Boerman, O. C.; Rijkers, D. T.; Liskamp, R. M. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes Org. Biomol. Chem. 2007, 5 (6) 935-944
39. von Maltzahn, G.; Ren, Y.; Park, J. H.; Min, D. H.; Kotamraju, V. R.; Jayakumar, J.; Fogal, V.; Sailor, M. J.; Ruoslahti, E.; Bhatia, S. N. In vivo tumor cell targeting with "click" nanoparticles Bioconjugate Chem. 2008, 19 (8) 1570-1578
40. Blackburn, W. H.; Dickerson, E. B.; Smith, M. H.; McDonald, J. F.; Lyon, L. A. Peptide-functionalized nanogels for targeted siRNA delivery Bioconjugate Chem. 2009, 20 (5) 960-968
41. Cai, W.; Ebrahimnejad, A.; Chen, K.; Cao, Q.; Li, Z. B.; Tice, D. A.; Chen, X. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice Eur. J. Nucl. Med. Mol. Imaging 2007, 34 (12) 2024-2036
42. Fox, B. P.; Tabone, C. J.; Kandpal, R. P. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines Biochem. Biophys. Res. Commun. 2006, 342 (4) 1263-1272
43. Vihanto, M. M.; Plock, J.; Erni, D.; Frey, B. M.; Frey, F. J.; Huynh-Do, U. Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin FASEB J. 2005, 19 (12) 1689-1691
44. Liu, Y.; Zhang, B.; Yan, B. Enabling anticancer therapeutics by nanoparticle carriers: the delivery of paclitaxel Int. J. Mol. Sci. 2011, 12 (7) 4395-4413
45. Singh, S.; Dash, A. K. Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges Crit. Rev. Ther. Drug Carrier Syst. 2009, 26 (4) 333-372
46. Coffman, K. T.; Hu, M.; Carles-Kinch, K.; Tice, D.; Donacki, N.; Munyon, K.; Kifle, G.; Woods, R.; Langermann, S.; Kiener, P. A.; Kinch, M. S. Differential EphA2 epitope display on normal versus malignant cells Cancer Res. 2003, 63 (22) 7907-7912
47. Wakayama, Y.; Miura, K.; Sabe, H.; Mochizuki, N. EphrinA1-EphA2 signal induces compaction and polarization of Madin-Darby canine kidney cells by inactivating ezrin through negative regulation of RhoA J. Biol. Chem. 2011, 286, 44243-44253
48. Miura, K.; Nam, J. M.; Kojima, C.; Mochizuki, N.; Sabe, H. EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts Mol. Biol. Cell 2009, 20 (7) 1949-1959
49. Flanagan, J. G.; Cheng, H. J.; Feldheim, D. A.; Hattori, M.; Lu, Q.; Vanderhaeghen, P. Alkaline phosphatase fusions of ligands or receptors as in situ probes for staining of cells, tissues, and embryos Methods Enzymol. 2000, 327, 19-35
50. Carlsson, S. R.; Roth, J.; Piller, F.; Fukuda, M. Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins carrying polylactosaminoglycan J. Biol. Chem. 1988, 263 (35) 18911-18919
51. Placzek, W. J.; Wei, J.; Kitada, S.; Zhai, D.; Reed, J. C.; Pellecchia, M. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy Cell Death Dis. 2010, 1, e40